Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – Equities researchers at SunTrust Banks issued their Q1 2020 earnings per share estimates for shares of Catalyst Pharmaceuticals in a research note issued to investors on Sunday, March 22nd. SunTrust Banks analyst J. Lee anticipates that the biopharmaceutical company will post earnings per share of $0.09 for the quarter. SunTrust Banks also issued estimates for Catalyst Pharmaceuticals’ Q2 2020 earnings at $0.11 EPS, Q3 2020 earnings at $0.11 EPS and Q4 2020 earnings at $0.11 EPS.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Monday, March 16th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.10 by ($0.02). Catalyst Pharmaceuticals had a net margin of 31.16% and a return on equity of 45.52%. The company had revenue of $30.12 million during the quarter, compared to the consensus estimate of $30.00 million.
Other equities research analysts have also recently issued research reports about the stock. BidaskClub cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 29th. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Catalyst Pharmaceuticals in a research note on Monday, December 23rd. Cantor Fitzgerald increased their target price on shares of Catalyst Pharmaceuticals from $11.00 to $12.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Finally, ValuEngine upgraded shares of Catalyst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, March 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $8.95.
NASDAQ CPRX opened at $3.89 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.54 and a current ratio of 4.62. The firm has a 50-day simple moving average of $4.10 and a 200 day simple moving average of $4.61. Catalyst Pharmaceuticals has a twelve month low of $2.23 and a twelve month high of $7.67. The stock has a market cap of $369.17 million, a PE ratio of 13.41 and a beta of 2.28.
A number of large investors have recently bought and sold shares of the stock. Alpine Global Management LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth approximately $58,000. Victory Capital Management Inc. increased its holdings in shares of Catalyst Pharmaceuticals by 53.3% in the fourth quarter. Victory Capital Management Inc. now owns 65,449 shares of the biopharmaceutical company’s stock valued at $269,000 after purchasing an additional 22,745 shares in the last quarter. Voloridge Investment Management LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the third quarter valued at approximately $93,000. Acadian Asset Management LLC increased its holdings in shares of Catalyst Pharmaceuticals by 182.9% in the fourth quarter. Acadian Asset Management LLC now owns 619,731 shares of the biopharmaceutical company’s stock valued at $2,324,000 after purchasing an additional 400,629 shares in the last quarter. Finally, Tower Research Capital LLC TRC acquired a new stake in shares of Catalyst Pharmaceuticals in the third quarter valued at approximately $27,000. 60.77% of the stock is owned by hedge funds and other institutional investors.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
Featured Story: Calculating net profit and net profit margin ratio
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.